DATELINE: — April 2, 2007 — ECI Biotech Inc. is pleased to announce that it has received small business innovative research (SBIR) funding for its rapid, point-of-care, wound infection diagnostic currently under development at the Company. The product is based on ECI’s patented ExpressDetect® technology platform. The diagnostic product will detect the presence of pathogens that infect chronic wounds in about 15 minutes and is intended to serve the growing $1.2B advanced wound care market. ECI’s technology can be applied broadly to rapid, point-of-care, wound diagnostic devices as well as to wound dressings for both professional and consumer use. The initial product is expected to launch globally in 2009.
